We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Updated International Trial Supports Cisplatin/Paclitaxel as Front-Line Treatment of Advanced Ovarian Cancer

Jul 1, 1998
Volume: 
7
  • Ovarian Cancer

 LOS ANGELES--The use of cisplatin (Platinol)/paclitaxel (Taxol)
for first-line treatment of advanced ovarian cancer gained additional
support from the final survival analysis of a major international
study presented at an ASCO scientific session.

Gavin C. E. Stuart, MD, of the University of Calgary, reported that
after a median 30 months of follow-up, women treated with
cis-platin/paclitaxel had significantly better overall survival and
progression-free survival than those treated with standard cyclophosphamide/cisplatin.

This survival benefit occurred even though patients whose disease
progressed on the cyclophosphamide/cisplatin arm could cross over to
a taxane-containing regimen. Women randomized to the
cisplatin/paclitaxel treatment arm had a reduction of about 30% in
risk of death (risk ratio adjusted for all prognostic factors, 0.71).

Dr. Stuart reported these results on behalf of the European-Canadian
Intergroup study, conducted by the EORTC, the NOCOVA, the NCI-Canada
Clinical Trials Group, and the Scottish Group.

This updated analysis confirmed preliminary results reported at ASCO
in 1997 and also confirmed results of the Gynecologic Oncology Group
study GOG-111, the first large randomized trial comparing the two combinations.

The European phase III trial included 680 patients with advanced
epithelial ovarian cancer (FIGO stages IIB, IIC, III, and IV). Women
with either suboptimally or optimally debulked ovarian cancer were eligible.

Patients were randomized to cyclophosphamide (750 mg/m²)
followed by cisplatin (75 mg/m²) every 3 weeks, or to paclitaxel
(175 mg/m² as a 3-hour infusion) followed by cisplatin every 3
weeks. Paclitaxel could be escalated to 200 mg/m² in the second
cycle in those patients who did not experience febrile neutropenia.

Patients were assessed after 3 cycles, and those with progressive
disease were removed from the protocol. All other patients were
scheduled to receive between 3 and 6 more cycles of chemotherapy.

Dr. Stuart also pointed out that patients could undergo interval
debulking surgery after completion of the first 3 cycles of treatment
if they were suboptimally debulked at the time of randomization.
"This strategy had previously been demonstrated to be effective
in a published EORTC trial," he said.

Progression-free survival rather than overall survival was the
primary endpoint. "This was done because of the wide
availability of paclitaxel at the time of the conduct of the study
and the anticipated high crossover rate for second-line
treatment," Dr. Stuart said. Of the 330 women randomized to
cyclophosphamide/cisplatin, 253 progressed on treatment, and 134
(52%) of these received a taxane.

Median Survival

Dr. Stuart reported that 668 patients were eligible for analysis at a
median follow-up of 30 months. "Median survival for patients on
the paclitaxel/cisplatin arm is 35 months vs about 25 months for
those on cyclophosphamide/cis-platin," he said. This was highly
significant at P < 0.001.

This survival advantage was apparent for both optimally debulked and
suboptimally debulked disease, he said, although the numbers were too
small to reach significance.

Progression-free survival, as reported last year, was 16 months in
the cisplatin/paclitaxel arm vs 12 months in the control arm, and the
advantage for cisplatin/paclitaxel was also demonstrated for both
optimally and suboptimally debulked disease.

Quality of life data are available for 210 patients. Ultimately, Dr.
Stuart said, there were no significant differences in effects on
global quality of life, cognitive functioning, insomnia, pain,
appetite loss, constipation, or fatigue, although there were
transient differences at various points over the 30-month period.

Related Articles

  • Promising Personalized Ovarian Cancer Vaccine Induces Immune Responses
  • FDA Approves Rucaparib for Recurrent Ovarian Cancer Maintenance Therapy
  • PARP-7 Amplification Mutations Linked to Prolonged Survival in Ovarian Cancer
  • Trial Participation May Offset Disparities in Ovarian Cancer Care
  • Despite Evolving Treatment for Ovarian Cancer, Late Diagnosis Remains a Challenge

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.